The Wegovy maker’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...
Novo Nordisk faces competition from Eli Lilly in new therapeutic areas. Read why I rate NONOF stock as a hold.
The pill version of Novo Nordisk’s (NVO) blockbuster drug Ozempic was found to cut the risk of heart attacks, strokes, and ...
A Watertown biotech says is received a $112 million investment led by the investment firm that manages the assets of the Novo ...
The Wegovy makers’s once-daily pill to treat type 2 diabetes has shown it cuts the risk of heart attacks and strokes in ...
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Seeking Alpha on MSN1h
Novo's Rybelsus results may not be clinically meaningful, Bernstein saysBernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...
A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients ...
The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...
On September 5, 2022, the China National Intellectual Property Association (China’s patent administrative office, hereinafter ...
Novo Nordisk A/S’s Rybelsus diabetes pill, a tablet version of Ozempic, reduced the risk of heart attacks and strokes in a large study that may drive broader use of the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback